FLT3 and acute myeloid leukemia: In another Phase 1 study, tuspetinib paired with venetoclax demonstrated a CRc rate of 30% in venetoclax-naive R/R AML patients, with promising results in FLT3-mutated AML subtypes (CRc of 37.5%) [33].